First Time Loading...
S

Silverback Therapeutics Inc
NASDAQ:SBTX

Watchlist Manager
Silverback Therapeutics Inc
NASDAQ:SBTX
Watchlist
Price: 5.87 USD 1.03% Market Closed
Updated: May 5, 2024

Silverback Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Silverback Therapeutics Inc
Cash from Financing Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
S
Silverback Therapeutics Inc
NASDAQ:SBTX
Cash from Financing Activities
$190.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$17.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
-17%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$5.1B
CAGR 3-Years
N/A
CAGR 5-Years
9%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
$21B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
23%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$562.2m
CAGR 3-Years
-4%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.8B
CAGR 3-Years
3%
CAGR 5-Years
-88%
CAGR 10-Years
N/A

See Also

What is Silverback Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
190.7m USD

Based on the financial report for Dec 31, 2022, Silverback Therapeutics Inc's Cash from Financing Activities amounts to 190.7m USD.

What is Silverback Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
30 964%

Over the last year, the Cash from Financing Activities growth was 30 964%.